In this review:
Imaging modality and frequency in seminoma testicular cancer surveillance
Surgery in early metastatic seminoma
Lenvatinib + pembrolizumab for advanced RCC
Sunitinib vs MET inhibitors in metastatic papillary RCC
Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma
Adjuvant nivolumab for high-risk MIUC
177Lu-PSMA-617 for metastatic castration-resistant prostate cancer
Apalutamide + ADT for metastatic castration-sensitive prostate cancer
Apalutamide and abiraterone acetate + prednisone for mCRPC
PI3K/AKT biomarkers for ipatasertib + abiraterone in mCRPC
Please login below to download this issue (PDF)